Pharmaceutical patient assistance programs — May 2025

SarahChen_PharmD said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

SarahChen_PharmD said:

...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

Following on from Dr.EndoIndy — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

DoseLogDan said:

SarahChen_PharmD said: ...regarding the discontinuation data for cost and coverage...

Insurance update relevant to cost and coverage: I just got my prior auth approved through Anthem after 1 attempts.

What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (PCOS + insulin resistance), and referencing the SURMOUNT trial data.

If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.

Closing the loop on my own question.

Follow-up — getting the denial reason in writing was the step that mattered. It named the criterion, and the criterion was a document I already had.

Dr.RenalNash said:

Insurance update relevant to cost and coverage: I just got my prior auth approved through Anthem after 1 attempts.

My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.